Literature DB >> 19382005

Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors.

Arto Mikkola1, Jussi Aro, Sakari Rannikko, Mirja Ruutu.   

Abstract

OBJECTIVE: To develop three prognostic groups for disease specific mortality based on the binary classified pretreatment variables age, haemoglobin concentration (Hb), erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), prostate-specific antigen (PSA), plasma testosterone and estradiol level in hormonally treated patients with metastatic prostate cancer (PCa).
MATERIAL AND METHODS: The present study comprised 200 Finnprostate 6 study patients, but data on all variables were not known for every patient. The patients were divided into three prognostic risk groups (Rgs) using the prognostically best set of pretreatment variables. The best set was found by backward stepwise selection and the effect of every excluded variable on the binary classification cut-off points of the remaining variables was checked and corrected when needed.
RESULTS: The best group of variables was ALP, PSA, ESR and age. All data were known in 142 patients. Patients were given one risk point each for ALP > 180 U/l (normal value 60-275 U/l), PSA > 35 microg/l, ESR > 80 mm/h and age < 60 years. Three risk groups were formed: Rg-a (0-1 risk points), Rg-b (2 risk points) and Rg-c (3-4 risk points). The risk of death from PCa increased statistically significantly with advancing prognostic group.
CONCLUSION: Patients with metastatic PCa can be divided into three statistically significantly different prognostic risk groups for PCa-specific mortality by using the binary classified pretreatment variables ALP, PSA, ESR and age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382005     DOI: 10.1080/00365590902836500

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  7 in total

1.  A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.

Authors:  Wei Lv; Hongxiang Shang; Xinqi Pei; Yule Chen; Hongjun Xie; Dalin He; Xinyang Wang; Lei Li
Journal:  Int Urol Nephrol       Date:  2016-11-11       Impact factor: 2.370

2.  Protein expression based multimarker analysis of breast cancer samples.

Authors:  Angela P Presson; Nam K Yoon; Lora Bagryanova; Vei Mah; Mohammad Alavi; Erin L Maresh; Ayyappan K Rajasekaran; Lee Goodglick; David Chia; Steve Horvath
Journal:  BMC Cancer       Date:  2011-06-08       Impact factor: 4.430

3.  Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.

Authors:  Yasuhide Miyoshi; Kazumi Noguchi; Masahiro Yanagisawa; Masataka Taguri; Satoshi Morita; Ichiro Ikeda; Kiyoshi Fujinami; Takeshi Miura; Kazuki Kobayashi; Hiroji Uemura
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

4.  Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.

Authors:  Yasuhide Miyoshi; Shuko Yoneyama; Takashi Kawahara; Yusuke Hattori; Jun-ichi Teranishi; Keiichi Kondo; Masatoshi Moriyama; Shigeo Takebayashi; Yumiko Yokomizo; Masahiro Yao; Hiroji Uemura; Kazumi Noguchi
Journal:  BMC Cancer       Date:  2016-02-19       Impact factor: 4.430

5.  The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.

Authors:  Farshid Dayyani; Amado J Zurita; Graciela M Nogueras-González; Rebecca Slack; Randall E Millikan; John C Araujo; Gary E Gallick; Christopher J Logothetis; Paul G Corn
Journal:  BMC Cancer       Date:  2016-09-06       Impact factor: 4.430

6.  Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.

Authors:  Keiichiro Mori; Florian Janisch; Mehdi Kardoust Parizi; Hadi Mostafaei; Ivan Lysenko; Dmitry V Enikeev; Shoji Kimura; Shin Egawa; Shahrokh F Shariat
Journal:  Int J Clin Oncol       Date:  2019-11-25       Impact factor: 3.402

7.  Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.

Authors:  Koichi Uemura; Yasuhide Miyoshi; Takashi Kawahara; Shuko Yoneyama; Yusuke Hattori; Jun-ichi Teranishi; Keiichi Kondo; Masatoshi Moriyama; Shigeo Takebayashi; Yumiko Yokomizo; Masahiro Yao; Hiroji Uemura; Kazumi Noguchi
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.